Introduction:

Next Generation Sequencing (NGS) platforms are able to sequence millions of fragments of DNA in parallel. It provides the researcher the opportunity to get a wide view of multiple samples, or get a deeper exploration of a small range of interested genes. Along with the costs are going down, more and more researchers are seeking the ways to apply this technology on enhancing individual patient care.

Utilizing the latest NGS technology, we offer highly specialized sequencing services, from short to long reads, from DNA to RNA, from genome to epigenome, to help researchers reveal useful genetic facts that benefits future discoveries. These services include:

Whole genome sequencing (WGS) is the thorough analysis of large DNA data sets which can identify single-nucleotide variants, indels, copy number variations and large structural variants.

Whole Exome sequencing provides a cost-effective alternative to WGS. As it targets the protein-coding region of the human genome, this technology makes it possible for researchers to process and decode exomes in a time- and cost-effective way.

RNA-Seq provides a precise and complete view of the transcriptomes and also makes it possible to identify novel transcripts, alternative splicing and gene fusion events. Besides, RNA-Seq provides an alternative and cost-effective approach for gene expression quantification.

Below are our advantages:

1. Limited starting materials? No worries. Lots of service companies require at least 1ug genomic DNA to start with. With our optimized protocol, we only require as low as 50 ng of genomic DNA, and we guarantee the same quality;

2. No fresh frozen tissue samples? No problem. We can deal with Formalin-fixed paraffin-embedded (FFPE) samples with as low as 50ng of genomic DNA as long as the majority of fragments are longer than 500bp.

3. Trying to do NGS using plasma samples? We could help. We could make high-quality DNA libraries using as low as 1ml plasma sample. Besides, we provide ChIP-Seq service using plasma sample. Using antibodies targeting marks of active promoters (H3K4me3), enhancers (H3K4me2, or H3K4me1), we could do immunoprecipitation from as low as 1-2ml plasma samples.  

Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.

Sample types we accept:

1, Purified nucleic acid samples

2, Cell Lysates and Tissue Lysates

3, Biofluids, such as plasma*, serum*, saliva, tear, etc.

4, FFPE slide/ FFPE extract

5, Customized sample types (please contact us to discuss)

Strategic Partnership with M20 Genomics, Advancing Single-Cell Multi-Omics for Precision Medicine

August 20, 2024 | BALTIMORE –  Complete Omics is thrilled to announce an electrifying partnership with M20 Genomics, a trailblazer in single-cell and spatial transcriptomics! Together, these industry leaders are…

Read more

Exciting News | Valid-NEO® Platform Secures U.S. Patent

May 12, 2024 | BALTIMORE –  Complete Omics is thrilled to announce that our Valid-NEO® platform’s “Method and System for Neoantigen Analysis” has been granted a U.S. patent after a rigorous…

Read more

Complete Omics Inc. Proudly Welcomes Proteomics Luminary Dr. Hui Zhang as Chief Scientific Officer

January 12, 2024 | BALTIMORE –  Complete Omics’ Clinical Proteomics team are thrilled to announce that Dr. Hui Zhang, a distinguished figure in the realm of proteomics, has joined the…

Read more

Some of our impacts